Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30154441 | 0.88 | GAA (0.48) | GAAALDH1A1GFERMAPTKDM4E | |
| SCHEMBL23832277 | 0.88 | GAA (0.48) | GAAALDH1A1GFERMAPTKDM4E | |
| SCHEMBL30154437 | 0.85 | MAPT (0.45) | ALDH1A1MAPTKDM4ECYP1A2CYP2C9 | |
| SCHEMBL23832225 | 0.85 | MAPT (0.45) | ALDH1A1MAPTKDM4ECYP1A2CYP2C9 | |
| SCHEMBL30154456 | 0.83 | GAA (0.49) | GAAALDH1A1GFERMAPTKDM4E | |
| SCHEMBL20943369 | 0.83 | GAA (0.49) | GAAALDH1A1GFERMAPTKDM4E | |
| SCHEMBL13172498 | 0.83 | ADRA1D (0.45) | GAAALDH1A1ADRA1DARMRGPRX4 | |
| SCHEMBL24172239 | 0.82 | ALDH1A1 (0.48) | GAAALDH1A1GFERMAPTKDM4E | |
| SCHEMBL5360300 | 0.82 | GAA (0.48) | GAAALDH1A1GFERMAPTKDM4E | |
| SCHEMBL5739424 | 0.82 | ALDH1A1 (0.55) | GAAALDH1A1GFERMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-8946204-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8937092-B2 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937092-B2 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937092-B2 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| EP-2760835-A1 | ARYL OR N-HETEROARYL SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2760836-A1 | AMINE SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8765733-B2 | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765733-B2 | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20050215550-A1 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-09-29 | — | — | US | disclosed |
| US-6875789-B2 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040209935-A1 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-21 | — | — | US | disclosed |
| US-6750239-B2 | USEFUL FOR TREATING DISEASE STATES IN MAMMALS THAT ARE ALLEVIATED BY A PROTEIN KINASE INHIBITOR, PARTICULARLY DISEASES SUCH AS CANCER, INFLAMMATORY DISORDERS, RESTENOSIS, AND CARDIOVASCULAR DISEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-15 | — | — | US | disclosed |
| EP-1423382-A2 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1423380-A1 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030144337-A1 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-31 | — | — | US | disclosed |
| US-20030139452-A1 | Pyrazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-24 | — | — | US | disclosed |
| WO-2003011854-A1 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011855-A2 | PYRAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209935-A1 | Pyrazole-derived kinase inhibitors and uses thereof | RAF1, MAP3K1, MAP3K3 | GAA 4212/4885ALDH1A1 2903/4885GFER 3779/4885 |
| US-20050215550-A1 | Pyrazole-derived kinase inhibitors and uses thereof | MAP3K19, MAP3K1, MAP3K3 | GAA 4333/4885ALDH1A1 3683/4885GFER 3298/4885 |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | GAA 2263/4885ALDH1A1 2943/4885GFER 1189/4885 |
| US-20030139452-A1 | Pyrazole-derived kinase inhibitors and uses thereof | RAF1, MAP3K1, MAP3K3 | GAA 4127/4885ALDH1A1 3191/4885GFER 3940/4885 |
| US-20030144337-A1 | Pyrazole-derived kinase inhibitors and uses thereof | RAF1, MAP3K1, MAP3K3 | GAA 4212/4885ALDH1A1 2903/4885GFER 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.